leadf
logo-loader
viewAcasti Pharma Inc

Acasti Pharma considering FDA's comments after receiving response to its CaPre TRILOGY trials briefing package

As reported in January, topline results from the TRILOGY 1 trial of its flagship drug candidate did not reach statistical significance due to an unusually large placebo effect

Acasti Pharma Inc -
TRILOGY 1 and TRILOGY 2 were Phase 3 studies on the drug, which is aimed at treating hypertriglyceridemia, known to contribute to heart disease

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) revealed Friday that it has received a written response from the US Food and Drug Administration (FDA) having submitted a New Drug Application (NDA) briefing package concerning its flagship drug candidate, CaPre to the regulator in April after the TRILOGY trials.

"Acasti and its expert advisors are carefully considering the FDA’s comments on the TRILOGY 1 data and will conduct further post-hoc analysis based on their feedback," the biotech said in a statement.

Acasti Pharma hopeful of path towards New Drug Application for CaPre as it submits TRILOGY 1 package

Topline results from the TRILOGY 1 trial, as reported in January, did not reach statistical significance due to an unusually large placebo effect.

The firm filed its FDA meeting request at the end of March, and the briefing package was intended to provide the regulator with a review of the relevant TRILOGY 1 data and audit findings, in a bid to "gain alignment on the interpretation of the TRILOGY 1 results and implications for TRILOGY 2".

Both were Phase 3 studies on the drug, which is krill-oil derived and aimed at treating hypertriglyceridemia, or high levels of triglycerides in the blood, which is known to contribute to heart disease.

"The FDA confirmed that it will require pivotal efficacy analyses for TRILOGY 2 to be performed on the full Intent to Treat (ITT) population as contemplated in the original Statistical Analysis Plan (SAP), and they supported the conduct of post-hoc analyses in TRILOGY 1 for exploratory purposes," the firm said.

"Consistent with the company’s prior disclosures, and depending on the outcome of TRILOGY 2, an additional clinical study may still be needed prior to an NDA submission," it added.

Acasti said it will host a conference call on Monday, June 29, 2020, at 1pm EST to discuss its financial results for the year ended March 31, 2020, as well as an update on the TRILOGY 1 and TRILOGY 2 Phase 3 trials of CaPre.

Shares in Acasti slipped around 14% on Friday in Toronto to C$1.03 each.

---Updates for share price---

Contact the author at giles@proactiveinvestors.com

Quick facts: Acasti Pharma Inc

Price: 0.27 CAD

TSX-V:ACST
Market: TSX-V
Market Cap: $26.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Acasti has 'put its finger on something very interesting' in...

Acasti Pharma Inc (NASDAQ:ACST)(CVE:ACST) COO Pierre Lemieux tells Proactive the last patient completed their final visit in its TRILOGY 1 trial of lead drug CaPre, which treats severe hypertriglyceridemia. Lemieux says the Quebec-based company is on its way to reporting results by the end of...

on 26/11/19

2 min read